○Kan Yonemori1, Shin Nishio2, Tomoka Usami3, Shinichiro Minobe4, Mayu Yunokawa5, Takashi Iwata6, Aikou Okamoto7, Yoichi Aoki8, Hiroaki Itamochi9, Munetaka Takekuma10, Kenichi Harano11, Keiko Yamamoto12, Hiroyuki Ugai12, Cumhur Tekin13, Sarper Toker13, Nicoletta Colombo14, Keiichi Fujiwara15, Kosei Hasegawa15 (1.Department of Medical Oncology, National Cancer Center Hospital, 2.Kurume University Hospital, Fukuoka, Japan, 3.Ehime University Hospital, Ehime, Japan, 4.Hokkaido Cancer Center, Hokkaido, Japan, 5.Cancer Institute Hospital of JFCR, Tokyo, Japan, 6.Keio University Hospital, Tokyo, Japan, 7.The Jikei University Hospital, Tokyo, Japan, 8.University of the Ryukyus Hospital, Okinawa, Japan, 9.Iwate Medical University Hospital, Iwate, Japan, 10.Shizuoka Cancer Center, Shizuoka, Japan, 11.National Cancer Center Hospital East, Kashiwa, Japan, 12.MSD K.K., Tokyo, Japan, 13.Merck & Co., Inc., Kenilworth, NJ, USA, 14.European Institute of Oncology IRCCS and Università degli Studi di Milano Bicocca, Milan, Italy, 15.Saitama Medical University International Medical Center, Saitama, Japan)
Session information
Oral Session
[O14] Oral Session 14 Gynecologic Cancer
【E】
Sat. Feb 19, 2022 3:00 PM - 4:10 PM Room 5 (Room B-1, 2F, Kyoto International Conference Center)
Chair:Noriyuki Katsumata(Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital ),Keiichi Fujiwara(Department of Gynecologic Oncology, Saitama Medical University International Medical Center)
Discussant:Mayu Yunokawa(Department of Gynecology Oncology and Department of Medical Oncology, Cancer Institute hospital of JFCR)
○Kan Yonemori1, Yasutoshi Kuboki2, Kosei Hasegawa3, Takashi Iwata4, Hidenori Kato5, Kazuhiro Takehara6, Yasuyuki Hirashima7, Hisamori Kato8, Chaitali Passey9, Jeppe Klint Buchbjerg10, Jeffrey R. Harris Harris9, Camilla Mondrup Andreassen10, Leonardo Nicacio11, Ibrahima Soumaoro9, Keiichi Fujiwara3 (1.National Cancer Center Hospital, 2.National Cancer Center Hospital East, 3.Saitama Medical University International Medical Center, 4.Keio University School of Medicine, 5.National Hospital Organization, Hokkaido Cancer Center, 6.NHO Shikoku Cancer Center, 7.Shizuoka Cancer Center, 8.Kanagawa Cancer Center, 9.Genmab US, Inc., 10.Genmab, 11.Seagen Inc.)
○Hiroshi Ando1, Savreet Bains2, Wenxi Tang3, Elyse Swallow3 (1.Genmab K.K., 2.Genmab US, Inc., 3.Analysis Group Inc.)
○Kazunori Honda1, Hirofumi Tsubouchi2, Masahiko Mori2, Shiro Suzuki2, Kohshiro Nakao3, Anri Azuma3, Shoji Nagao4, Takashi Shibutani4, Takahiro Koyanagi5, Izumi Kohara6, Shuko Tamaki7, Midori Yabuki7, Lida Teng8, Yusuke Kajimoto8,9, Ataru Igarashi8,10 (1.Department of Clinical Oncology, Aichi Cancer Center Hospital, 2.Department of Gynecologic Oncology, Aichi Cancer Center Hospital, 3.Department of Obstetrics and Gynecology, Gunma University Hospital, 4.Department of Gynecology, Hyogo Cancer Center, 5.Department of Obstetrics and Gynecology, Jichi Medical University, 6.School of nursing, Jichi Medical University, 7.Nursing Department, Saitama Medical University International Medical Center, 8.東京大学 大学院薬学系研究科, 9.Oncology Science Unit, MSD K.K., 10.Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine)